Megaloblastic anaemia is a red blood cell disorder due to the inhibition of DNA synthesis during erythropioesis.
Mitotically, the inhibition of the DNA synthesis impaires the progression of the cell cycle development from G2 to (M) stage.
Megaloblastic anaemia is a red blood cell disorder due to the inhibition of DNA synthesis during erythropioesis.
Mitotically, the inhibition of the DNA synthesis impaires the progression of the cell cycle development from G2 to (M) stage.
Megaloblastic anaemia is a type of anaemia characterized by the formation of unusually large, abnormal and immature red blood cells called as megaloblasts by the bone marrow, which are released into the blood. To know more visit here: www.lazoi.com
causes of macrocytic anemia pathopysiology, sign and symptoms and the difference between macrocytic anemia megaloblastIc anemia. causes of hypersegmented neutrophils and its association between them. investigation and medical management plus pictures illustration.
Aplastic anemia is one of the stem cell disorder which leads to pancytopenia in the peripheral blood and decrease production of all cell line in bone marrow. it require bone marrow transplantation to cure the patient.
amyloidosis(including history,physical and chemical properties, classification, variants, staining characteristics, lab diagnosis,morphological patterns according to organ involved ,), basically for undergraduates and residents in pathology
A decrease in red blood cells when the body can't absorb enough red blood cells.It is an organ specific autoimmune diseases in which the body’s immune system attacks the lining of the stomach.
It was considered as a deadly disease due to the lack of available treatment.
Pernicious anemia is most common in caucasian persons of north European ancestry than in other racial groups.
chronic myeloid leukemia, CML, epidemiology, BCR ABL1 gene, philadelphia chromosome, t(9;22), CML incidence, etiology of CML, pathophysiology of CML, phases of CML, treatment of CML, Allogenic stem cell transplant, TKI therapy for CML, Sokal index for CML,
This presentation is about anemia of chronic disease, nowadays also called as anemia of Inflammation. I have dealt with anemia in CKD and malignancy in detail.
Megaloblastic anaemia is a type of anaemia characterized by the formation of unusually large, abnormal and immature red blood cells called as megaloblasts by the bone marrow, which are released into the blood. To know more visit here: www.lazoi.com
causes of macrocytic anemia pathopysiology, sign and symptoms and the difference between macrocytic anemia megaloblastIc anemia. causes of hypersegmented neutrophils and its association between them. investigation and medical management plus pictures illustration.
Aplastic anemia is one of the stem cell disorder which leads to pancytopenia in the peripheral blood and decrease production of all cell line in bone marrow. it require bone marrow transplantation to cure the patient.
amyloidosis(including history,physical and chemical properties, classification, variants, staining characteristics, lab diagnosis,morphological patterns according to organ involved ,), basically for undergraduates and residents in pathology
A decrease in red blood cells when the body can't absorb enough red blood cells.It is an organ specific autoimmune diseases in which the body’s immune system attacks the lining of the stomach.
It was considered as a deadly disease due to the lack of available treatment.
Pernicious anemia is most common in caucasian persons of north European ancestry than in other racial groups.
chronic myeloid leukemia, CML, epidemiology, BCR ABL1 gene, philadelphia chromosome, t(9;22), CML incidence, etiology of CML, pathophysiology of CML, phases of CML, treatment of CML, Allogenic stem cell transplant, TKI therapy for CML, Sokal index for CML,
This presentation is about anemia of chronic disease, nowadays also called as anemia of Inflammation. I have dealt with anemia in CKD and malignancy in detail.
Iron deficiency anemia is one of the nutritional deficiency anemia, and the most common microcytic hypochromic anemia. it is also one of the common anemia in Pakistan. Pregnant and lactating are most commonly affected.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
2. Introduction
• Anemia is functionally defined as an insufficient RBC
mass to adequately deliver oxygen to peripheral
tissues.
• Anemia is considered to be present if the hemoglobin
(Hb) concentration or the hematocrit (Hct) is below the
lower limit of the 95% reference interval for the
individual’s age,sex, and geographic location .
• Anemia may be absolute, when red blood cell mass is
decreased, or relative, when associated with a higher
plasma volume.
• Causes of absolute anemia
• 1.impaired red cell production
• 2. increased erythrocyte destruction or loss in excess of
the ability of the marrow to replace these losses.
3. • Iron deficiency is the most common anaemia.
• 83-90% of all anemia constitute IDA
• Every day about 30 mg iron is used to make
new hemoglobin.
• Daily iron loss is around 1 mg.
• In women menstruation and childbirth
increase iron losses to about 1.5 mg/day.
4. • The total content of iron in the body - about 4.2g.
From them:
- 75-80% belongs to the hemoglobin
- 20 - 25% reserve
- 5-10% part of the myoglobin
-1% is part of the enzyme for the tissue respiration
5. DIETARY IRON
• There are 2 types of iron in the diet; heme
iron and non-heme iron.
• Heme iron is present in Hb containing animal
food like meat, liver & spleen.
• Non-heme iron is obtained from cereals,
vegetables & beans.
7. • Most body iron is present in hemoglobin in
circulating red cells
• The macrophages of the reticuloendotelial
system store iron released from hemoglobin
as ferritin and hemosiderin.
• In the plasma, total iron averages 110 µg/dL
• Majority bound to the transferrin (capacity
to bind 330 µg of iron per deciliter)
• So only one third of transferrin is saturated.
8. IRON METABOLISM
• Iron concentration (Fe)
• N: 50-150 g/dl
• Total Iron Binding Capacity
• N: 250-450 g/dl
• Transferrin saturation
• Transferrin receptor concentration
• Ferritin concentration
• N: 50-300 g/l
10. IRON ABSORPTION
• Site- Proximal small intestine i.e. duodenum (first
part- maximum absorption) and jejunum.
• 10% of dietary iron is absorbed
• it is determined by intraluminal factor i.e. pH and
redox potential.
• Therapeutic ferrous iron is well absorbed on
empty stomach.
• Haem iron is not affected by ingestion of other
food items.
• Heme iron → Acid and gastric juices release it
from apoprotein → Oxidised → hemin → directly
absorb through mucosal cell intact.
11. INHIBITORS OF IRON ABSORPTION
• Food with polyphenol compounds
– Cereals like sorghum & oats
– Vegetables such as spinach and spices
– Beverages like tea, coffee, cocoa and wine.
– A single cup of tea taken with meal reduces iron
absorption by up to 11%.
• Food containing phytic acid i.e. Bran
• Cow’s milk due to its high calcium & casein
contents.
12. Promoters of Iron Absorption
• Foods containing ascorbic acid like citrus
fruits, broccoli & other dark green vegetables
• Foods containing muscle protein
• Food fermentation aids iron absorption by
reducing the phytate content of diet
13. Iron absorption at molecular level
• Iron is converted from Fe3+ to
Fe2+ by ferrireductase
(DCYTB).
• Fe2+ transported across
mucosal surface of enterocyte
by DMT1, stored as ferritin.
• Ferritin releases Fe2+ which is
transported across basolateral
surface of enterocyte with
help of ferroportin .
• Fe2+ converted back to Fe3+ by
Hephaestin .
• Fe3+ binds to transferrin in
plasma.
14. Regulation of Iron Absorption
• Regulated at two stages
– Mucosal uptake
– At stage of transfer to blood
• 1. HIF-2 ά- a mediator of cellular adaptation to
hypoxia, regulates DMT1 transcription and thus
regulates mucosal uptake of iron because
mucosal uptake depend on DMT 1.
• 2. Iron transfer to the plasma depends on the
requirements of the erythron for iron and the
level of iron stores.
• This regulation is mediated directly by hepcidin.
16. • The reticuloendothelial macrophages play a
major role in recycling iron resulting from the
degradation of haemoglobin from senescent
erythrocytes.
• They engulf red blood cells and release the
iron within using haem oxygenase.
• The protein transporting iron to plasma is
ferroportin.
17. Ferroportin and Hepcidin
• Hepcidin- its synthesis is controlled at molecular level.
• Interaction of diferric transferrin,bone morphogenetic
proteins (BMPs), interleukin (IL)-6 and other
inflammatory cytokines with cell surface receptors TfR1,
TfR2, hemojuvelin (HJV) and IL-6 receptor lead to
upregulation of the hepcidin gene.
• Mechanism of action- it binds to both TfR1 and TfR2,
decreasing the affinity of each for transferrin.
– Stabilization and endocytosis of TfR2 stimulates hepcidin
production
– Diferric transferrin displaces the protein HFE from TfR1,
leaving it free to interact with TfR2, thus stimulating
hepcidin production in response to plasma iron levels.
18. • Increased erythropoiesis causes decreased hepcidin.
Hepcidine function
– Blocks ferroportin
– Prevents absorption of iron from enterocytes.
– Prevents iron exportation from macrophages.
– Increased in inflammation.
– Leads to reduced serum iron, microcytic anemia, and
incomplete response to iron therapy.
• Ferroportin
– Transporter protein of iron in enterocytes and macrophages.
– Blocked by hepcidin .
19. Newborn Iron Stores
• Endowed with 75 mg/kg of iron at birth
• Dependent on hemoglobin concentration at
birth (majority of iron in circulating RBCs)
• Depleted by 3 months in low birth weight
infants without supplementation
• Depleted by age 5-6 months in term infants
• Delayed cord clamping (by 2 minutes) leads to
higher ferritin and iron stores at 6 months of
age
20. Iron storage
• Iron stored in two forms
– Soluble ferritin
– Insoluble hemosiderin- denatured form of ferritin
in which the protein shells have partly degraded,
allowing the iron cores to aggregate.
• Hemosiderin deposits are seen on Prussian-blue
positivity after staining of tissue sections with
potassium ferrocyanide in acid.
21. Regulation of Iron Metabolism
• Iron metabolism is regulated post transcriptionally by iron
regulatory proteins- IRP 1 and IRP 2.
• The conformation of IRP1 required for binding to mRNA
iron-responsive elements (IREs).
• IRP2 are directly affected by the amount of iron within a
cell.
• When the labile iron pool is deficient of iron, IRP1 has
an available binding site for IRE.
• When the labile iron pool is saturated with iron, the iron
binds to IRP1 to produce a 4Fe-4S cluster which blocks the
IRE binding site and prevents IRP1 binding to the IRE.
• In the presence of iron, IRP2 is degraded.
• Regulation of iron proteins by IRP on basis of location of IRE
on mRNA
– at 3’UTR- Stabiles translocation of TfR & DMT 1
– 5’UTR- inhibit translation of mRNA
22. IRON TRANSPORT
• Transferrin is the major protein responsible for
transporting iron in the body
• Transferrin receptors, located in almost all cells of
the body, can bind two molecules of transferrin.
• One molecule of transferrin binds two molecules
of iron.
• Both transferrin saturation & transferrin
receptors are important in assessing iron status
23. • Transferrin, when incompletely saturated with
iron, exists in four forms:
1. Apotranferrin
2. Monoferrric transferrin A
3. Monoferrric transferrin B
4. Diferric Transferrin
• There distribution may be determined by urea-
polyacrylamide electrophoresis.
• The plasma iron pool (transferrin-bound iron)
is about 3 mg.
24. Other iron transporter proteins
1. Haptoglobin- Serum glycoprotein
• It binds with Hemoglobin άẞ dimer released into
the bloodstream by hemolysis.
• Hemoglobin–haptoglobin complex is removed
from plasma by macrophages having receptor CD
163.
2. Hemopexin- Plasma glycoprotein that binds heme
and transports the haem to cells by a process that
involves receptor-mediated endocytosis
25. 3. Ferritin-
– present in low conc in plasma.
– Mostly appears as glycosylated and has low content of iron.
– It is also released into the circulation as a result of tissue
damage.
4. Non-transferrin-bound iron-
– Iron that is not bound to transferrin.
– Have low molecular mass and can be bound by specific iron
chelators.
– Chemical form is not known but rapidly removed from
circulation by liver.
– This removal involve zinc transporter ZIP14.
26. AT RISK GROUPS
1. Infants
2. Under 5 children
3. Children of school age
4. Women of child bearing age
5. Geriatric age group
27. Causes of iron deficiency
• Chronic blood loss
• Increased demand
• Malabsorbtion of iron
• Inadequate iron intake
• Intravascular hemolysis and hemoglobinuria-
hemosiderinuria
• Combinations
29. Decreased intake
• Decreased iron in the diet
– Vegetarian diet
– Low socioeconomic status
– Lack of balanced diet or poor intake
– Alcoholism
• Decreased absorbtion
– Gastric surgery
– Achlorhydria
– Duodenal pathology
– Chronic renal failure patients
– Coeliac Sprue
– Pica
30. Increased iron loss
• Menorrhagia
• Gastrointestinal
hemorrhage
• P.Ulcer
• Oesophagitis
• Varices
• Hiatal hernia
• Malignancy
• Angiodysplasia
• Diverticulosis
• Meckel
diverticula
• Colitis or
imperforated
bowel disease
• Hemorrhoids
• NSAID use
• Parasites
31. Increased iron loss
• Bleeding disorder
• Pulmonary lesions with bleeding
• Hemoglobinuria – hemosiderinuria (chronic
intravascular hemolysis)
• Hemodialysis
• Hematuria (chronic)
• Frequent donation
– 250 mg iron /unit-blood
32. Pathogenesis of iron deficiency anemia
• There are three pathogenic factors
– Impaired Hb synthesis d/t reduced iron supply
– Generalized defect in cellular proliferation
– Survival of erythroid precursor and erythrocytes is
reduced
When transferrin saturation ‹15%, marrow supply of
iron reduced and is inadequate to meet basal
requirement for Hb production.
– erythrocyte protoporphyrin raised
– each RBC contain less Hb so microcytic and
hypochromic
33. Clinical features of iron deficiency
anemia
• Fatigue and Other Nonspecific Symptoms
– irritability, palpitations, dizziness, breathlessness,
headache, and fatigue
• Neuromuscular System
– impair muscular performance, abnormalities in
muscle metabolism , behavioral disturbances,
– Neurologic development in infants and scholastic
performance in older children may be impaired.
– Sometimes neuralgia pains, vasomotor disturbances,
or numbness and tingling.
34.
35. Epithelial tissues
Site findings
Nails Flattening
Koilonychia
Tongue Soreness
Mild papillary atrophy
Absence of filiform papillae
Mouth Angular stomatitis
Hypopharynx Dysphagia
Esophageal webs
Stomach Achlorhydria
Gastritis
36. Plummer-Vinson syndrome
• The most common
anatomic lesion is a
“web” of mucosa at the
juncture between the
hypopharynx and the
esophagus
37. • Immunity and Infection
– Defective lymphocyte-mediated immunity and impaired
bacterial killing by phagocytes.
• Pica
– “craving to eat earth”
• Pagophagia is, defined as the purposeful eating of at
least one tray of ice daily for 2 months,
• Food pica- compulsively eating one food, often
something that is brittle and makes a crunching sound
when chewed.
• Genitourinary System- Disturbances in menstruation,
• Skeletal System
– diploic spaces may be widened, and the outer tables
thinned
38. Developmental Stages of Iron
Deficiency Anemia (WHO)
• Pre-latent –
– reduction in iron stores without reduced serum iron levels
– Hb, MCV, Transferrin saturation- Normal, Iron absorption -
increase, Serum ferritin and marrow iron reduced
– no clinical manifestation
• Latent-
– iron stores are exhausted, but the blood hemoglobin level
remains normal
– index of the blood within the standard
– clinical picture is caused by the sideropenic syndrome
• Iron Deficiency Anemia
– blood hemoglobin concentration falls below the lower limit of
normal
– the clinical manifestations in the form of sideropenic syndrome
and general anemic symptoms
39. Stages in the Development of Iron
Deficiency
Stage 1 (Prelatent) Stage 2 (Latent) Stage 3 (Anemia)
Bone marrow iron Reduced Absent Absent
Serum ferritin Reduced <12 μg/L <12 μg/L
Transferrin saturation Normal <16% <16%
Free erythrocyte protoporphyrin, zinc
protoporphyrin
Normal increased increased
Serum transferrin receptor Normal increased increased
Reticulocyte hemoglobin content Normal reduced reduced
Hemoglobin Normal Normal Reduced
Mean corpuscular volume Normal Normal Reduced
Symptoms Fatigue, malaise Pallor, pica, in some
patients
45. Bone marrow findings
• BONE MARROW
– Early stage - Normoblastic hyperplasia
– Normoblasts - smaller than normal
• deficient in hemoglobin
• Irregular shaped with frayed margins
– polychromatic and pyknotic cytoplasm of
erythroblasts is vacuolated and irregular in outline
(micronormoblastic erythropoiesis)
– absence of stainable iron
• WBCs- Giant neutrophil bands or metamyelocytes
• Storage iron is absent
48. Lab tests of iron deficiency of
increased severity
NORMAL Fe deficiency
Without anemia
(prelatent)
Fe deficiency
With mild anemia
(latent)
Fe deficiency
With severe anemia
(IDA)
Serum Iron 60-150 60-150 <60 <40
Iron Binding
Capacity
300-360 300-390 350-400 >410
Saturation 25-55 30 <15 <10
Hemoglobin Normal Normal 9-12 6-7
Serum Ferritin 40-200 <20 <10 0-10
49. Methods for assessing iron status
Measurements Reference range Diagnostic Value Confounding factors
1. Hemoglobin
concentration
Male: 13–17 g/dl
Female: 12–15 g/dl
• Defining anemia and
assessing its
severity.
• Response to a
therapeutic
trial of iron confirms
iron deficiency
anaemia (IDA).
Other causes of anemia
besides iron deficiency
2. Red cell indices
Mean cell volume
Mean cell
haemoglobin (MCH)
83–101 fl
27–32 pg
Low values indicate iron
deficient erythropoiesis.
May be reduced in
disorders of
haemoglobin synthesis,
other than iron deficiency
(thalassaemia, sideroblastic
anaemias, anaemia of
chronic disease)
3. Tissue iron supply
Serum iron 10–30 µmol/l Low values in iron
deficiency, high
values in iron overload
Reduced in acute and
chronic disease; labile,
use of fasting morning
sample reduces variability
50. MEASUREMENT REFERENCE RANGE
(ADULTS)
DIAGNOSTIC USE CONFOUNDING FACTORS
Total iron binding
capacity (TIBC)
47–70 µmol/l High values -tissue iron
deficiency
Low value- iron overload
Rarely used on its own.
Reliable reference ranges
not available
Transferrin
saturation (TS)
(iron/TIBC × 100)
16–50% Low- iron deficiency
anemia
Reduced in acute and
chronic
disease
Iron supply to the bone
marrow
Serum transferrin
receptor (sTfR)
Red cell zinc
protoporphyrin
(ZPP)
2.8–8.5 mg/l
<80 µmol/mol Hb
Reduced red cell ferritin or
increased ZPP, sTfR and %
hypochromic red cells
indicate impaired iron
supply to the bone
marrow.
• Identifying early iron
deficiency and, with a
measure of iron
stores.
• Distinguishing
this from anemia of
chronic disease.
• sTfR concentration is
related to extent of
erythroid activity as
well as iron supply to
cells.
• ZPP may be increased
by other causes of
impaired iron
incorporation
into haem
(sideroblastic
anaemias, lead
poisoning,
inflammation)
51. MEASUREMENT REFERENCE RANGE
(ADULTS)
DIAGNOSTIC USE CONFOUNDING
FACTORS
Iron stores
Serum ferritin
Male 15–300 µg/l
Female 15–200 µg/l
Correlated with body iron
stores from deficiency to
overload
• Increased: as acute-
phase protein
• By release of tissue
ferritin after organ
damage.
• Decreased:
vitamin C deficiency
Bone marrow Grade • Graded as absent,
present or increased
• Used to d/b ACD and
IDA.
Adequate sample
required
52. Serum Iron
• Reference interval is 50–160 µg/dL
• Determination of iron status requires-
– Estimate of the amount of haemoglobin iron (usually by measuring the
haemoglobin concentration (Hb) in the blood).
– Level of storage iron (measuring serum ferritin concentration).
• Assay of serum iron- It is modification of method recommended by the
International Council for Standardization in Haematology (ICSH) and is
based on the development of a coloured complex when ferrous iron
released by serum protein denaturation in the presence of reducing
agent is treated with a chromogen solution.
• Alternate methods-
• 1. Microtitre plate method
• 2. Automated Methods for Serum Iron- non-precipitation method ,
available from Randox Ltd .
• INTERPRETATION
• Level reduced in - Iron deficiency anemia
– Anemia of chronic diseases
– Infections
53. Serum ferritin
• Normal value- 15–300 µg/L (Men>women)
• Water-soluble complex of iron hydroxide with the protein
apoferritin.
• It is located in cells of the liver, spleen, bone marrow .
• Ferritin assay- Immunoradiometric assay ( 1st method)
• MOA- Excess radiolabelled antibody react with ferritin and antibody
not bound to ferritin was removed with an immunoadsorbent.
• Interpretation –
• Ferritin is the basic protein which deposits iron.
• Serum ferritin concentration reflects iron reserve of individual.
• Reduced in iron deficiency anemia.
• It is acute phase reactant so raised in some hepatocellular diseases,
malignancies, and inflammatory diseases, so may give
disproportionately high estimate of storage iron .
• Age between 6 months- 15 yrs reference value is low.
54. Transferrin
• Transferrin has a very high affinity for iron at neutral pH
and iron release takes place through a specific
membrane receptor
LIMITATION
• The concentration of transferrin is subjected to the
daily variations
• Acute inflammation contributes to lowering the
transferrin level
CLINICAL SIGNIFICANCE
• Basic clinical index for the differentiation between the
iron-deficiency ([TF]↑) and hemolytic anemia ([TF]↓)
• More precise index than total iron binding capacity
• After the liberation of iron from the complex, TF ion of
Fe3+ must be restored into Fe2+
55. Serum (Total) Iron-Binding Capacity
(TIBC)
• Iron in plasma binds to transferrin and TIBC is the measure of
this protein.
• The additional iron-binding capacity of transferrin is known
as the unsaturated iron-binding capacity (UIBC).
• TIBC = UIBC + serum iron concentration .
• TIBC(µmol/l) = Transferrin conc (gm/l) × 25
• Estimation of TIBC- By adding an excess of iron to a solution
and measuring the iron retained in solution after the addition
of a suitable reagent such as ‘light’ magnesium carbonate or
an ion-exchange resin that removes excess iron.
• Principle
Excess iron as ferric chloride is added to serum. Any iron that
does not bind to transferrin is removed with excess
magnesium carbonate. The iron concentration of the iron-
saturated serum is then measured.
• Raised in iron deficiency anemia
56. UIBC DETERMINATION
• The UIBC may be determined by methods that detect
iron remaining and able to bind to chromogen, after
adding a standard and excess amount of iron to the
serum.
• The UIBC is the difference between the amount
added and the amount binding to the chromogen.
• METHODS-
– Chromogen solution
– Microtitre tray
• UIBC is being evaluated as a screening test for iron
overload in genetic haemochromatosis.
57. Serum Transferrin (Beta-globulin)
• Main function - transport of absorbed iron in the depot (liver,
spleen), into the medullary erythroid predecessors and into
the reticulocytes.
• Basic place of synthesis - liver.
• Reference interval for adults is 200–300 µg/dL (2.0–3.0 g/l )
• 1 mg of transferrin binds 1.4 µg of iron.
• ESTIMATION OF SERUM TRANSFERRIN-
• by an immunological assay-Rate immunonephelometric
methods
• INTERPRETATION
• An increase in the content of transferrin with lowering in the
level of iron of serum is characteristic for the iron-deficiency
state.
• A decrease in the level of transferrin can be with the damage
of the liver (different genesis) and with the loss of protein (for
example, in nephrotic syndrome).
• The level of transferrin is increased in the last term of
pregnancy.
58. Transferrin saturation
• The transferrin saturation is the ratio of the serum iron
concentration and the TIBC expressed as a percentage
• Normally, this is 20%–55%.
• A transferrin saturation of <16% is usually considered to
indicate an inadequate iron supply for erythropoiesis.
• Used for detection of genetic haemochromatosis.
• Normal diurnal variation serum iron is as much as 30% with
highest values in the morning and lowest values late in the
day.
• fasting morning blood specimens are preferred for the
diagnosis of iron deficiency.
• Transferrin Index
It is serum iron concentration ( µmol/l) divided by the
transferrin concentration (determined immunologically and
expressed as µmol/l)
59. SERUM TRANSFERRIN RECEPTOR
• There are two types of
transferrin receptors TfR1
and TfR2 .
• TfR1 is essential for tissue
iron delivery
• Transferrin binds to
TfR1, the complex is
internalized and iron is
released when the pH of
the internal vesicles is
reduced to about 5.5 .
60. Estimation of transferrin receptors
(TfR)
• Transferrin receptors have been purified from placenta
and from serum.
• Three enzymes immunoassay kits
• Fully automated, diagnostic, immunoassay systems .
• Four different units (nmol/l, µg/ml, mg/l and ku/l)
• INTERPRETATION
• sTfR concentrations are high in neonates and decline
until adult concentrations are reached at 17 years.
• Increased during pregnancy
61. sTfR CONCENTRATION CONDITION
Increased Increased erythroid proliferation:
Autoimmune haemolytic anaemia
Hereditary spherocytosis
ẞ Thalassaemia intermedia or major
ẞ Thalassaemia/HbE
Haemoglobin H disease
Sickle cell anaemia
Polycythaemia vera
Decreased tissue iron stores:
Iron deficiency anaemia
Normal to increased Idiopathic myelofibrosis
Myelodysplastic syndrome
Chronic lymphocytic leukaemia
Normal Haemochromatosis
Acute and chronic myeloid leukaemia
Most lymphoid malignancies
Solid tumours
Anaemia of chronic disease
Decreased Chronic renal failure
Aplastic anaemia
After bone marrow transplantation
62. Erythrocyte Porphyrins
• Protoporphyrin IX is the immediate precursor to haem.
• The enzyme ferrochelatase is able to insert ferrous iron to produce haem
or zinc cation to form zinc protoporphyrin (ZPP).
• When iron supply to ferrochelatase is limiting, ZPP increases.
• When ferrochelatase is limiting, free protoporphyrin accumulates.
• Normal reference value is adults is less than 70 µmol/mol haem.
• ANALYSIS- Two dedicated analysers are available: the Proto Fluor Z
from Helena Laboratories, Beaumont, Texas (www.helena.com) and the
ZPP 206D from Aviv Biomedical Inc
• The measurement of EP levels as an indicator of iron deficiency has
particular advantages in pediatric hematology.
• Mean ZPP values Female > Male
• Level of porphyrins in Iron def anemia according to WHO
• Children younger than age 5 years- >61 µmol/mol haem
• all other subjects, levels should be >70 µmol/mol haem.
• Erythrocyte porphyrins became elevated before the development of
anemia
• One of the earliest indicators of iron defiiency
63. Serum Transferrin Receptor–to–
Serum Ferritin Ratio (TfR/F)
• New approach to estimate total body iron
stores.
• Have limited value in identifying anemia of
chronic disease (ACD)
• Better utilized in identifying iron defiiency
anemia coexisting with ACD
64. Differential diagnosis of Microcytic
anaemia
Iron deficiency
anemia
Anemia of
chronic disease
Thalassaemia
Sideroblastic
anemia
MCV Reduced Low normal or
normal
Low Low in inherited
but normal in
acquired
Serum iron Reduced Reduced Normal Raised
Serum TIBC Raised Reduced Normal Normal
Serum Ferritin Reduced Normal or raised Normal Raised
Iron in BM Absent Present Present Present
65. Iron Deficiency in Infancy
and Childhood
• INFANTS- There are rapid changes in iron
status in the first year of life as fetal Hb is
replaced by adult hemoglobin.
• The serum ferritin concentration is a less
useful because of rapid decline in
concentration in the first 6 months and the
low concentrations generally found in children
older than 6 months of age.
66. • Children- reason for detecting iron deficiency
is to identify those who will respond to iron
therapy.
• Best predictor of response was the initial Hb,
• Serum ferritin, transferrin saturation and
erythrocyte protoporphyrin (EP) had lower
efficiencies.
• ZPP provides a useful indicator of iron
deficient erythropoiesis
67. Iron Balance in Pregnancy
Iron Fate Mean Amount (mg) Range (mg)
Lost to fetus 270 200–370
Lost in placenta, cord 90 30–170
Lost with bleeding at
delivery
150 90–310
Normal body iron loss 170 150–200
Added to expanded
red blood cell mass
450 200–600
Total 1,130 670–1,650
Returned to stores
when
450 200–600
Net loss (over 9 mo) 680 470–1,050
68. Iron deficiency in Pregnancy
• In early pregnancy serum ferritin concentrations
usually provide a reliable indication of iron
deficiency
• Haemodilution in the 2nd and 3rd trimesters of
pregnancy reduces the concentrations of all
measures of iron status.
• determination of values as ratios (ZPP µmol/
mol haem, transferrin saturation and
sTfR/ferritin) should be more reliable.
69. • In healthy women who were not anaemic and
who were supplemented with iron, serum iron,
transferrin saturation and serum ferritin fell from
the 1st to the 3rd trimester and increased after
delivery; TIBC increased during pregnancy and fell
after delivery.
• sTfR concentrations increased (approximately
two-fold) during pregnancy and this probably
reflects increased erythropoiesis.
70. CONCLUSION
• Body iron status can usually be assessed by
considering the Hb, red cell indices and serum
ferritin concentration, along with evidence of
inflammation, infection and liver disease.
•